journal article·2024-02-21

Orchestrating Precision within the Tumor Microenvironment by Biomimetic Nanoprodrugs for Effective Tumor Therapy

Yuemin Wang, Hong Xu, Xiaoming Huang, Yuyue Zhang, Yongping Lu, Jing Cheng, Xinyuan Xu, Jianshu Li, Haochen Yao, Xingyu Chen

Publisher page

Abstract

Malignant tumors are still one of the most deadly diseases that threaten human life and health. However, developing new drugs is challenging due to lengthy trials, funding constraints, and regulatory approval procedures. Consequently, researchers have devoted themselves to transforming some clinically approved old drugs into antitumor drugs with certain active ingredients, which have become an attractive alternative. Disulfiram (DSF), an antialcohol medication, can rapidly metabolize in the physiological environment into diethyldithiocarbamate (DTC) which can readily react with Cu 2+ ions in situ to form the highly toxic bis( N, N -diethyldithiocarbamate)–copper(II) (CuET) complex. In this study, DSF is loaded into mesoporous dopamine nanocarriers and surface-chelated with tannin and Cu 2+ to construct M-MDTC nanoprodrugs under the camouflage of K7 tumor cell membranes. After intravenous injection, M-MDTC nanoprodrugs successfully reach the tumor sites with the help of mediated cell membranes. Under slightly acidic pH and photothermal stimulation conditions, DSF and Cu 2+ are simultaneously released, forming a highly toxic CuET to kill tumor cells in situ. The generated CuET can also induce immunogenic cell death of tumor cells, increase the proportion of CD86 + CD80 + cells, and promote dendritic cell maturation. In vitro and in vivo studies of M-MDTC nanoprodrugs have shown excellent tumor-cell-killing ability and solid tumor suppression. This approach enables in situ amplification of chemotherapy in the tumor microenvironment, achieving an effective antitumor treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Phagocytosis and Immune Regulation · Autophagy in Disease and Therapy · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu 610065, China

Orthopedic Research Institution, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu 610041, China

Sichuan Eye Hospital, AIER Eye Hospital Group, No. 153, Tianfu Fourth Street, High-Tech Zone, Chengdu 610047, China

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Med-X Center for Materials, Sichuan University, Chengdu 610041, China

Hepatobiliary and Pancreatic Surgery Department, General Surgery Center, First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin 130021, China

College of Medicine, Southwest Jiaotong University, Chengdu 610003, China

Funding

State Key Laboratory of Polymer Materials Engineering · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China · JinFeng Laboratory, Chongqing, China

References (42)

Show source-provided references
1. 10.3390/cancers1322586910.3390/cancers13225869 ↗
2. 10.1016/s0140-6736(17)31451-410.1016/s0140-6736(17)31451-4 ↗
3. 10.1016/j.clnu.2022.04.02010.1016/j.clnu.2022.04.020 ↗
4. 10.1016/j.semcancer.2019.08.01410.1016/j.semcancer.2019.08.014 ↗
5. 10.1186/s12951-023-01826-110.1186/s12951-023-01826-1 ↗
6. 10.1002/adma.20210740610.1002/adma.202107406 ↗
7. 10.1016/j.jconrel.2022.03.02310.1016/j.jconrel.2022.03.023 ↗
8. 10.1016/j.drudis.2016.07.00310.1016/j.drudis.2016.07.003 ↗
9. 10.1038/s41467-017-00680-810.1038/s41467-017-00680-8 ↗
10. 10.1016/j.drudis.2021.10.01010.1016/j.drudis.2021.10.010 ↗
11. 10.1016/j.canlet.2017.10.02010.1016/j.canlet.2017.10.020 ↗
12. 10.2174/221173850666618031612262010.2174/2211738506666180316122620 ↗
13. 10.1158/1535-7163.MCT-22-006610.1158/1535-7163.MCT-22-0066 ↗
14. 10.3390/cancers1201013810.3390/cancers12010138 ↗
15. 10.1634/theoncologist.2014-042410.1634/theoncologist.2014-0424 ↗
16. 10.1016/j.carbpol.2021.11784610.1016/j.carbpol.2021.117846 ↗
17. 10.1016/j.biomaterials.2022.12188010.1016/j.biomaterials.2022.121880 ↗
18. 10.1021/acsnano.0c0884810.1021/acsnano.0c08848 ↗
19. 10.1016/j.apsb.2021.01.01310.1016/j.apsb.2021.01.013 ↗
20. 10.1021/acsabm.1c0052110.1021/acsabm.1c00521 ↗
21. 10.1016/j.jconrel.2020.01.00110.1016/j.jconrel.2020.01.001 ↗
22. 10.1016/j.apsb.2022.11.00110.1016/j.apsb.2022.11.001 ↗
23. 10.1016/j.biomaterials.2020.12020810.1016/j.biomaterials.2020.120208 ↗
24. 10.1039/C7NR01857F10.1039/C7NR01857F ↗
25. 10.1021/nn103254g10.1021/nn103254g ↗
26. 10.1016/j.bioactmat.2022.09.02510.1016/j.bioactmat.2022.09.025 ↗
27. 10.1186/s12951-021-01109-710.1186/s12951-021-01109-7 ↗
28. 10.1021/jacs.6b0655810.1021/jacs.6b06558 ↗
29. 10.1016/j.cell.2009.05.04510.1016/j.cell.2009.05.045 ↗
30. 10.1038/nrd349910.1038/nrd3499 ↗
31. 10.1074/jbc.M20959020010.1074/jbc.M209590200 ↗
32. 10.1021/acsnano.0c0077110.1021/acsnano.0c00771 ↗
33. 10.1016/j.biomaterials.2020.12015910.1016/j.biomaterials.2020.120159 ↗
34. 10.1016/j.cclet.2021.10.05710.1016/j.cclet.2021.10.057 ↗
35. 10.34133/2022/976868710.34133/2022/9768687 ↗
36. 10.1016/j.apsb.2022.11.00310.1016/j.apsb.2022.11.003 ↗
37. 10.7150/thno.5092810.7150/thno.50928 ↗
38. 10.1016/j.jconrel.2021.07.04010.1016/j.jconrel.2021.07.040 ↗
39. 10.1186/s12943-021-01376-w10.1186/s12943-021-01376-w ↗
40. 10.1084/jem.191.3.42310.1084/jem.191.3.423 ↗
41. 10.1002/adhm.20170136910.1002/adhm.201701369 ↗
42. 10.1002/smll.20220311410.1002/smll.202203114 ↗